Following the release of Q4 and full-year 2025 results, Altria regained a Buy rating based on enhanced visibility into its earnings and dividend trajectory through 2028. Management reaffirmed a mid-single-digit annual growth target for adjusted diluted EPS, supported by share repurchases and disciplined cost management. Dividend payments, currently yielding over 7%, are projected to increase at a compound annual growth rate of approximately 5% by 2028. Investors welcomed this clarity, citing the combination of stable cash flows and a shareholder-friendly capital return policy as key drivers of medium-term total return potential.

In Q4 2025, Altria’s shipment volumes of combustible products declined by around 3%, reflecting broader industry headwinds. The company countered this volume softness with sequential price increases averaging 6% across its leading smokeable portfolio, protecting gross margins near 70%. This aggressive pricing strategy helped maintain segment profitability at levels roughly flat year-over-year, underscoring management’s ability to pass rising input and regulatory costs onto the consumer without eroding overall profitability.

Altria will present at the Consumer Analyst Group of New York conference in Orlando on February 18, 2026, at 1:00 p.m. Eastern Time, featuring CEO Billy Gifford and CFO Sal Mancuso. The live, listen-only webcast will cover recent operating metrics, product development milestones in the tobacco-free segment, and long-term capital allocation priorities. Pre-event registration is required at altria.com/webcasts, and an archived replay will be accessible thereafter, offering investors a detailed update on portfolio diversification efforts and strategic initiatives.

Despite progress toward smoke-free product development, Altria’s core combustible segment still represents 87.5% of total revenue and continues to contract. Marlboro’s retail share slipped below 40% in Q4 2025, while the oral tobacco business grew by less than 1% year-over-year, remaining financially immaterial. With the forward price-to-earnings multiple hovering near 12x and consensus EPS growth expectations tempered by regulatory uncertainty, analysts have lowered their recommendation to Hold, citing constrained valuation upside at current levels.